Scleroderma and Lupus Health Study Claims No Environmental Link To Disease PDF Print E-mail
Friday, 08 January 2010 22:09
taken from http://www.flickr.com/photos/h_de_c/3291978657/ via creative commonsThe Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of scleroderma and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed statistically significantly higher than expected among Caucasian females. No specific associations with environmental exposures were identified.

The study did confirm that a previous diagnosis of rheumatoid arthritis was associated with scleroderma and lupus among current and former South Boston residents. Further, the study also found that a family history of specific rheumatic diseases was significantly associated with a diagnosis of scleroderma and lupus.

The Department of Public Health's study was initiated in 1998, as a result of concerns raised by the South Boston community and then-State Senator Stephen F. Lynch, who now represents Massachusetts' 9th congressional district. At that time, the community expressed concerns about a perceived increase in the number of women who had grown up in South Boston and were later diagnosed with scleroderma. Community members also expressed concern about possible environmental exposure.

"The release of this study represents more than ten years of collaboration between the Massachusetts Department of Public Health and the South Boston community to address concerns of the prevalence of scleroderma and lupus," Congressman Stephen F. Lynch said. "I am pleased to see that this study has been completed and the results will guide future research and help those living with these chronic diseases."

DPH Commissioner John Auerbach added, "These types of studies are important and enhance our collaboration with community partners to improve public health."

DPH responded to the communities’ concerns by collaborating with clinical researchers and epidemiologists at Boston Medical Center, Tufts Medical Center and the South Boston Community Health Center to conduct a retrospective case-control study to investigate the occurrences of both diseases and to identify possible contributing factors (environmental and non-environmental) among individuals with scleroderma and lupus. In addition, DPH established a South Boston Community Advisory Committee to facilitate community outreach and ongoing communication.

Study participants were interviewed about their residential, occupational, medical, family and reproductive histories, as well as hobbies and recreational activities in the area. The study also investigated possible historical exposures to a number of sources of environmental pollution, as well as spatial and temporal (time) patterns among current and former residents with these diseases.

Source: Office of Health and Human Services (EOHHS)

If you're logged in, you can download a copy of the report, presentation, and questions and answers below.

 
More articles :

» Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in...

» Endothelin Receptor Antagonists for the Treatment of Raynaud’s Phenomenon and Digital Ulcers in Systemic Sclerosis

Kait Arefiev, David F. Fiorentino, and Lorinda ChungDivision of Immunology and Rheumatology, Departments of Dermatology and Medicine, Stanford University School of Medicine, Palo Alto VA Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304,...

» Face Exercises for Scleroderma

Scleroderma is caused by too much collagen in your body, which causes hardening, thickening and tightening of your skin and connective tissues. In localized scleroderma, only your skin is involved; systemic scleroderma damages your inner organs,...

» Scleroderma Patients At Greater Risk Of Myocardial Infarction Within First Year

According to the first large population-based cohort study of its kind, patients with Systemic Sclerosis or were found to be at a greater than eightfold increased risk of having an acute (MI) during their first year after diagnosis. After that...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...

» Positive Phase II Results for AIMSPRO In Scleroderma Announced

announced yesterday, positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic...